

# **2019 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets**

<https://marketpublishers.com/r/29854641434EN.html>

Date: February 2019

Pages: 278

Price: US\$ 2,199.00 (Single User License)

ID: 29854641434EN

## **Abstracts**

The ongoing clinical trial research report- “2019 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials Study” analyzes the current scenario of all active Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer trials across the world. The report presents top level analysis of global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials by-

Region (Asia Pacific, Europe, Middle East Africa and Americas)

Countries

Trial Phase

Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)

Type of the trial (Interventional, Observational)

Sponsor Type (Companies, Universities, Government Bodies etc)

Enrollment across types, sponsor types, geographies, current status and phases

The report also identifies the potential drug candidates under development for treatment of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer on the basis of intervention type ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer trials.

The research work is prepared through extensive and continuous research on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

## **REPORT SCOPE AND COVERAGE:**

All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.

Drug candidates currently being researched for administering Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer patients are identified

The report includes panorama of ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials across the globe

Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided

Companies and universities focusing on Metastatic Hormone Refractory

(Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)

Average Enrollment number, insights into enrollment trends, company wise enrollment are included

Both interventional and observational studies are analyzed

News and latest developments for the past one year are presented in the report

## Contents

### 1. TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

### 2. EXECUTIVE SUMMARY

2.1 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials Overview, 2019

2.2 Premium Insights into Ongoing Clinical Trials

2.2.1 Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials by Region

2.2.2 Average Enrollment of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials

2.2.3 Companies participating in Ongoing Trials

2.2.4 Drugs under Study for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Treatment, 2019

### 3. REGION WISE METASTATIC HORMONE REFRACTORY (CASTRATION RESISTANT, ANDROGEN-INDEPENDENT) PROSTATE CANCER CLINICAL TRIALS

3.1 Asia Pacific Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials by Country

3.2 Europe Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials by Country

3.3 North America Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials by Country

3.4 Middle East and Africa Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials by Country

3.5 South and Central America Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials by Country

### 4. METASTATIC HORMONE REFRACTORY (CASTRATION RESISTANT, ANDROGEN-INDEPENDENT) PROSTATE CANCER CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Metastatic Hormone Refractory (Castration Resistant,

*2019 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinic...*

Androgen-Independent) Prostate Cancer Clinical Trials

4.2 Phase wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials

4.3 Trial Status wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials

4.4 Trial Type wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials

## **5. METASTATIC HORMONE REFRACTORY (CASTRATION RESISTANT, ANDROGEN-INDEPENDENT) PROSTATE CANCER AVERAGE ENROLLMENT TRENDS**

5.1 Average Enrollment in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials by Year

5.2 Average Enrollment in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials by Phase

5.3 Average Enrollment in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials by Status

5.4 Average Enrollment in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials by Type of Trial

## **6. COMPANIES PARTICIPATING IN ONGOING METASTATIC HORMONE REFRACTORY (CASTRATION RESISTANT, ANDROGEN-INDEPENDENT) PROSTATE CANCER CLINICAL TRIALS**

6.1 Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials by Sponsor Type

6.2 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Average Enrollment by Sponsor Type

6.3 Subjects Recruited by Leading Sponsors

## **7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS**

7.1 Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials- Phase

7.2 Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials- Phase

7.3 Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials- Phase

7.4 Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Trials- Phase

## **8. APPENDIX**

8.1 Report Guidance

8.2 Research Methodology

8.3 Abbreviations

8.4 Definitions

8.5 Sources

8.6 Publisher Expertise

## List Of Figures

### LIST OF FIGURES

Figure 1: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials by Region, 2019

Figure 2: Country wise Clinical Trials, 2019

Figure 3: Country wise Average Enrolment, 2019

Figure 4: Asia Pacific – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Figure 5: Europe – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Figure 6: Middle East Africa – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Figure 7: North America – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Figure 8: South and Central America – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Figure 9: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials by Phase

Figure 10: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials by Trial Status

Figure 11: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials by Type

Figure 12: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials by Sponsor Type

Figure 13: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials by Leading Sponsors

Figure 14: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Average Enrollment by Phase

Figure 15: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Average Enrollment by Trial Status

Figure 16: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Average Enrollment by Type

Figure 17: Metastatic Hormone Refractory (Castration Resistant, Androgen-

Independent) Prostate Cancer- Average Enrolment by Type of Sponsors

Figure 18: Metastatic Hormone Refractory (Castration Resistant, Androgen-

Independent) Prostate Cancer- Enrolment by Leading Sponsors

Figure 19: VPAResearch- Research Methodology



## List Of Tables

### LIST OF TABLES

Table 1: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials Snapshot- 2019

Table 2: Ongoing Trials by Region, 2019

Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019

Table 4: Asia Pacific – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Table 5: Europe – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Table 6: Middle East Africa – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Table 7: North America – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Table 8: South and Central America – Country wise Ongoing Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials and Enrolment

Table 9: Clinical Trials by Phase

Table 10: Clinical Trials by Trial Status

Table 11: Clinical Trials by Type

Table 12: Clinical Trials by Sponsor Type

Table 13: Clinical Trials by Leading Sponsors

Table 14: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Average Enrollment by Phase

Table 15: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Average Enrollment by Trial Status

Table 16: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Average Enrollment by Type

Table 17: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer- Average Enrolment by Type of Sponsors

Table 18: Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer- Enrolment by Leading Sponsors

## I would like to order

Product name: 2019 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

Product link: <https://marketpublishers.com/r/29854641434EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/29854641434EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970